^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    palupiprant (AN0025)

    i
    Other names: AN0025, E 7046, E-7046, AN-0025, E7046, TPST-7317
    Associations

    News

    Trials
    Company:
    Adlai Nortye, Eisai
    Drug class:
    PGE2 inhibitor, PGE4 antagonist
    Related drugs:
    Associations

    News

    Trials
    6ms
    Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=47, Completed, Adlai Nortye Biopharma Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    Tecentriq (atezolizumab) • buparlisib (AN2025) • palupiprant (AN0025)
    8ms
    A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants (clinicaltrials.gov)
    P1, N=0, Withdrawn, Rutgers, The State University of New Jersey | N=24 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    Imfinzi (durvalumab) • palupiprant (AN0025)
    10ms
    AN0025 and Chemoradiotherapy Combination in Esophageal Cancer (clinicaltrials.gov)
    P1, N=32, Suspended, Adlai Nortye Biopharma Co., Ltd. | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial primary completion date
    |
    carboplatin • paclitaxel • palupiprant (AN0025)
    1year
    Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=63, Active, not recruiting, Adlai Nortye Biopharma Co., Ltd. | Trial primary completion date: Sep 2024 --> Dec 2024
    Trial primary completion date
    |
    Tecentriq (atezolizumab) • buparlisib (AN2025) • palupiprant (AN0025)
    over1year
    Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=63, Active, not recruiting, Adlai Nortye Biopharma Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    Tecentriq (atezolizumab) • buparlisib (AN2025) • palupiprant (AN0025)
    over1year
    AN0025 and Chemoradiotherapy Combination in Esophageal Cancer (clinicaltrials.gov)
    P1, N=32, Suspended, Adlai Nortye Biopharma Co., Ltd. | Recruiting --> Suspended
    Trial suspension • Combination therapy • Metastases
    |
    carboplatin • paclitaxel • palupiprant (AN0025)
    over1year
    Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=63, Recruiting, Adlai Nortye Biopharma Co., Ltd. | Trial completion date: Jun 2024 --> Jan 2025 | Trial primary completion date: Mar 2024 --> Sep 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    Tecentriq (atezolizumab) • buparlisib (AN2025) • palupiprant (AN0025)
    over1year
    Role of COX-2/PGE2/EP4 Axis-induced Macrophage Functional Activation in NSCLC Development (PubMed, Zhongguo Fei Ai Za Zhi)
    During NSCLC development, the COX-2/PGE2/EP4 axis may promote tumor progression by inducing macrophage functional activation, and EP4 may be a potential new target for tumor immunotherapy. This study provides new perspectives and ideas for in-depth exploration of the mechanisms of NSCLC development, as well as a theoretical basis for the development of new therapeutic strategies for NSCLC.
    Journal • IO biomarker
    |
    CDH1 (Cadherin 1) • CD163 (CD163 Molecule) • CD31 (Platelet and endothelial cell adhesion molecule 1) • CDH2 (Cadherin 2) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • CD86 (CD86 Molecule)
    |
    CDH1 expression • CD31 expression
    |
    palupiprant (AN0025)
    almost2years
    KEYNOTE 879: AN0025 and Pembrolizumab Combination in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=63, Active, not recruiting, Adlai Nortye Biopharma Co., Ltd. | Trial completion date: Nov 2025 --> Jan 2025 | Trial primary completion date: Apr 2025 --> May 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • palupiprant (AN0025)
    2years
    Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=63, Recruiting, Adlai Nortye Biopharma Co., Ltd. | Phase classification: P1a --> P1 | Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Sep 2023 --> Mar 2024
    Phase classification • Trial completion date • Trial primary completion date
    |
    Tecentriq (atezolizumab) • buparlisib (AN2025) • palupiprant (AN0025)
    over2years
    Discovery of Novel, Selective Prostaglandin EP4 Receptor Antagonists with Efficacy in Cancer Models. (PubMed, ACS Med Chem Lett)
    Due to favorable pharmacokinetics properties and good oral bioavailability (F = 76%), compound 36 was chosen for in vivo efficacy studies. Compound 36 inhibited tumor growth in a CT-26 colon cancer xenograft better than E7046 and a combination of 36 with capecitabine significantly suppressed tumor growth (TGI up to 94.26%) in mouse models.
    Preclinical • Journal
    |
    capecitabine • palupiprant (AN0025)
    over2years
    Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1a, N=63, Recruiting, Adlai Nortye Biopharma Co., Ltd. | Trial completion date: Nov 2022 --> Dec 2023 | Trial primary completion date: Sep 2022 --> Sep 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    PIK3CA mutation
    |
    Tecentriq (atezolizumab) • buparlisib (AN2025) • palupiprant (AN0025)